Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOFACITINIB Cause Liver function test increased? 1,221 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 1,221 reports of Liver function test increased have been filed in association with TOFACITINIB (XELJANZ XR). This represents 0.8% of all adverse event reports for TOFACITINIB.

1,221
Reports of Liver function test increased with TOFACITINIB
0.8%
of all TOFACITINIB reports
473
Deaths
462
Hospitalizations

How Dangerous Is Liver function test increased From TOFACITINIB?

Of the 1,221 reports, 473 (38.7%) resulted in death, 462 (37.8%) required hospitalization, and 375 (30.7%) were considered life-threatening.

Is Liver function test increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 1,221 reports have been filed with the FAERS database.

What Other Side Effects Does TOFACITINIB Cause?

Drug ineffective (30,382) Pain (21,659) Condition aggravated (16,925) Arthralgia (15,640) Fatigue (13,551) Rheumatoid arthritis (12,277) Off label use (11,736) Headache (11,061) Joint swelling (10,686) Malaise (9,040)

What Other Drugs Cause Liver function test increased?

METHOTREXATE (3,839) ADALIMUMAB (2,070) ETANERCEPT (1,829) LEFLUNOMIDE (1,521) ABATACEPT (1,415) TOCILIZUMAB (1,406) RITUXIMAB (1,325) SULFASALAZINE (1,263) HYDROXYCHLOROQUINE (1,259) INFLIXIMAB (1,191)

Which TOFACITINIB Alternatives Have Lower Liver function test increased Risk?

TOFACITINIB vs TOFERSEN TOFACITINIB vs TOLNAFTATE TOFACITINIB vs TOLODODEKIN ALFA TOFACITINIB vs TOLTERODINE TOFACITINIB vs TOLVAPTAN

Related Pages

TOFACITINIB Full Profile All Liver function test increased Reports All Drugs Causing Liver function test increased TOFACITINIB Demographics